This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
by Zacks Equity Research
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
by Zacks Equity Research
Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
by Zacks Equity Research
Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.
Bristol Myers' (BMY) Application for UC Drug Validated by EMA
by Zacks Equity Research
Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.
Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study
by Zacks Equity Research
Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.
Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies
by Zacks Equity Research
Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
by Zacks Equity Research
We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.
Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
by Zacks Equity Research
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion
by Zacks Equity Research
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash
by Zacks Equity Research
Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.
Editas (EDIT) Submits Application to Start Study on EDIT-301
by Zacks Equity Research
Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
by Zacks Equity Research
Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.
Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH
by Zacks Equity Research
Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy
by Zacks Equity Research
Johnson & Johnson's (JNJ) Janssen acquires rights to investigational gene therapy, HMR59, for the treatment of geographic atrophy.
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study
by Zacks Equity Research
Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.
Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.
Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.